Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Debt: 2016-2025

Historic Total Debt for Rhythm Pharmaceuticals (RYTM) over the last 1 years, with Sep 2025 value amounting to $109.0 million.

  • Rhythm Pharmaceuticals' Total Debt was N/A to $109.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.0 million, marking a year-over-year change of. This contributed to the annual value of $109.8 million for FY2024, which is 3.45% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Total Debt is $109.0 million, which was down 0.75% from $109.8 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Total Debt registered a high of $109.8 million during Q4 2024, and its lowest value of $106.1 million during Q4 2023.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Total Debt value was $109.5 million (recorded in 2025), while the average stood at $108.8 million.
  • Data for Rhythm Pharmaceuticals' Total Debt shows a peak YoY climbed of 3.45% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Rhythm Pharmaceuticals' Total Debt stood at $106.1 million in 2023, then rose by 3.45% to $109.8 million in 2024, then reached $109.0 million in 2025.
  • Its Total Debt stands at $109.0 million for Q3 2025, versus $109.8 million for Q2 2025 and $109.5 million for Q1 2025.